BEIJING--(BUSINESS WIRE)--China Medical Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic systems and tumor therapy systems, today announced that it has completed its previously announced acquisition of a FISH business. The acquisition is expected to expand and diversify the Company’s existing product portfolio and complement the Company’s existing ECLIA diagnostic products by providing proprietary tests for the diagnosis of prenatal and postnatal disorders as well various cancers. The new business will further strengthen China Medical’s leading position in the rapidly-growing area of diagnostic testing in China.
